23 citations,
January 2001 in “Chemical & Pharmaceutical Bulletin” New pregnane derivatives are effective at inhibiting an enzyme linked to hair loss and reducing oil gland activity.
17 citations,
October 1994 in “The Journal of Clinical Endocrinology and Metabolism” 2 citations,
September 1997 in “Archives of Dermatology” June 2019 in “Journal of Drug Delivery and Therapeutics” 184 citations,
January 2000 in “European Urology” Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
21 citations,
September 1994 in “The Journal of Clinical Endocrinology and Metabolism” 9 citations,
August 1992 in “The Journal of Clinical Endocrinology and Metabolism” September 2018 in “The Journal of Urology” 61 citations,
September 1994 in “The Journal of Clinical Endocrinology and Metabolism” 5 citations,
January 2022 in “Clinical cancer investigation journal” Certain Dibenzo derivatives may help treat prostate cancer.
March 2022 in “Skin appendage disorders” 7 citations,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” 37 citations,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
31 citations,
September 2008 in “International Journal of Andrology” 5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.
20 citations,
October 2018 in “The Journal of Urology” Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.
6 citations,
May 2020 in “JAMA Ophthalmology” Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.
6 citations,
January 2018 in “Pharmacoepidemiology and Drug Safety” Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
5 citations,
December 2021 in “Pediatric investigation” Testosterone undecanoate safely and effectively increased penis size in male children with 5-alpha-reductase deficiency.
2 citations,
January 2017 in “Annals of Dermatology” Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
May 2012 in “Journal of Clinical Oncology” Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.
52 citations,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
117 citations,
March 2013 in “Journal of the European Academy of Dermatology and Venereology” No effective treatment for frontal fibrosing alopecia was found, but oral 5-alpha-reductase inhibitors had the best response; for lichen planopilaris, topical corticosteroids were commonly used but had a high relapse rate.
68 citations,
April 2002 in “Journal of Alternative and Complementary Medicine” Natural 5AR inhibitors effectively improve mild to moderate hair loss in men.
65 citations,
April 2002 in “Journal of Alternative and Complementary Medicine” Plant extracts effectively reduce hair loss and increase growth, offering a safe alternative treatment.
50 citations,
August 1985 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Spironolactone reduces the enzyme activity that converts testosterone to DHT, helping treat excessive hair growth in women.
49 citations,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
32 citations,
May 2013 in “The Journal of Urology” Using finasteride or dutasteride does not increase the risk of male breast cancer.